19 October 2015 - Pfizer Inc. today announced that investigational antibody-drug conjugate (ADC) inotuzumab ozogamicin received breakthrough therapy designation from the U.S. Food and Drug Administration for acute lymphoblastic leukaemia.

For more details, go to: http://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_inotuzumab_ozogamicin_receives_fda_breakthrough_therapy_designation_for_acute_lymphoblastic_leukemia_all